SOURCE: Five Star Equities

Five Star Equities

April 16, 2012 08:20 ET

Ruling in Texas Could Provide New Opportunities for Stem Cell Companies

Five Star Equities Provides Stock Research on BioTime and Cytori Therapeutics

NEW YORK, NY--(Marketwire - Apr 16, 2012) - March has shown to be a troublesome month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has fallen over 16 percent in the last month, in comparison the SPDR S&P Biotech (ETF) has fallen just over 2 percent. A new ruling in Texas could potentially provide new opportunities for the industry. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on BioTime, Inc. (NYSE: BTX) and Cytori Therapeutics Inc. (NASDAQ: CYTX).

Access to the full company reports can be found at:

www.FiveStarEquities.com/BTX

www.FiveStarEquities.com/CYTX

In Texas they are expected to vote on new rules that would allow doctors in the state to offer experimental treatments involving adult stem cells to patients without FDA approval. The Texas medical board drafted the new rules after Gov. Rick Perry, who appoints all the members of the Medical Board, was treated with his own stem cells to help recover from a back injury. The new proposed rules would allow doctors to avoid the FDA as long as they obtain patient consent and secured approval from an "independent" review board.

"It is my hope that Texas will become the world's leader in the research and use of adult stem cells," Mr. Perry wrote in a July letter to the president of the Texas Medical Board.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, reported financial results for the fourth quarter and year ended December 31, 2011. For the quarter ended December 31, 2011, on a consolidated basis, total revenue was $1.6 million, up $0.2 million or 15% from $1.4 million for the same period one year ago. The increase in revenue year-over-year in the fourth quarter 2011 is primarily attributable to an increase in the sale of research products.

Cytori Therapeutics achieved important objectives towards validating Celution technology in multiple large market indications, clarified the U.S. cardiovascular pathway with FDA, and raised cash to fund 2012 objectives. In particular, the Company reported positive long-term outcomes from two clinical trials, initiated a European pivotal heart attack trial, and in January 2012 received FDA approval to initiate a U.S. clinical trial for chronic myocardial ischemia (CMI).

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.FiveStarEquities.com/disclaimer

Contact Information